Fortis Life Sciences Acquires nanoComposix

Fortis Life Sciences Acquires Abcore

March 2, 2022

Biotechnology

Fortis Life Sciences has acquired Abcore, an antibody discovery platform specializing in nanobody technologies, to expand Fortis’ antibody product and service capabilities. The acquisition brings Abcore’s end-to-end discovery and custom antibody production capabilities into the Fortis platform to accelerate commercial and operational scale-up for biopharma and diagnostic customers.

Biocomposites Takes Minority Stake in Renovos Biologics

July 5, 2023

Biotechnology

Biocomposites has taken a minority equity stake in Renovos Biologics to support development and pre-market approval of the RENOVITE nanoclay therapeutic delivery platform. The investment will give Renovos access to Biocomposites' development expertise and global distribution network; Biocomposites CEO Michael Harris will join Renovos' board.

Biocomposites Acquires Artoss GmbH (NanoBone technology)

June 6, 2023

Medical Devices

Biocomposites, the UK-based medical devices company, has acquired Artoss GmbH, a Rostock, Germany-based maker of NanoBone bone graft substitutes. The acquisition adds Artoss' proprietary NanoBone technology to Biocomposites' product portfolio and gives the technology access to Biocomposites' global distribution network.

Fortis Life Sciences Acquires International Point of Care

July 12, 2023

Medical Devices

Fortis Life Sciences, LLC has acquired Toronto-based International Point of Care, Inc. (IPOC). The acquisition adds IPOC’s 36,000 sq. ft. GMP and ISO 13485:2016 manufacturing facility and capabilities (lyophilized reagents, membranes, recombinant proteins, and controls) to Fortis’ diagnostics manufacturing platform, enabling end-to-end customizable solutions for immunodiagnostic and molecular diagnostic customers.

Element Materials Technology Acquires Nanosyn

October 11, 2021

Pharmaceuticals

Element Materials Technology acquired Nanosyn, a San Francisco Bay Area-based contract development and manufacturing organization (CDMO) focused on drug discovery and small-batch API manufacturing, to strengthen Element’s pharmaceuticals and biopharmaceutical services in North America. Nanosyn operates three Bay Area facilities and has a team of more than 75 scientists, and the deal expands Element’s end-to-end life sciences capabilities from discovery through clinical development and regulatory support.

Novopor Advanced Science Acquires FAR Chemical from CPS Performance Materials Group

January 23, 2026

Manufacturing

Novopor Advanced Science, a Bain Capital–backed performance chemicals and materials CDMO, has acquired FAR Chemical from CPS Performance Materials Group to expand its U.S. footprint and add capabilities in complex specialty chemistries. The deal integrates FAR Chemical's expertise in custom and hazardous specialty chemical manufacturing—serving electronics, aerospace & defense, and coatings/adhesives end markets—into the Novopor platform.